Presentation Operator Message
Operator (Operator)
Good morning, and welcome to the Hansa Biopharma Presents Phase II Trial Data in GBS and Indirect Treatment Comparison Conference Call. [Operator
I
USA
EnglishUK
EnglishIndia
EnglishAustralia
EnglishCanada
EnglishFrance
FrançaisSuisse
FrançaisEspaña
EspañolDeutschland
DeutschÖsterreich
DeutschSchweiz
DeutschBelgië
NederlandsNederland
NederlandsItalia
ItalianoSverige
Svenska
Mercato chiuso -
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
22,72 SEK | -2,07% |
|
-11,94% | -42,04% |
10/02 | Redeye abbassa il fair value di Hansa Biopharma a 120 SEK (130) | FW |
07/02 | HC Wainwright abbassa il prezzo obiettivo di Hansa Biopharma a 143 corone svedesi (175), ribadendo Buy - BN | FW |
Presentation Operator Message
Operator (Operator)
Good morning, and welcome to the Hansa Biopharma Presents Phase II Trial Data in GBS and Indirect Treatment Comparison Conference Call. [Operator
I